NCT05704647View on ClinicalTrials.gov

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Melanoma (Skin)
Interventions
DRUG

BMS-986213 (Relatlimab-Nivolumab FDC)

Given by IV (vein)

DRUG

Nivolumab

Given by IV (vein)

DRUG

Relatlimab

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER